Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CDX-527 |
Synonyms | |
Therapy Description |
CDX-527 is a tetravalent human antibody targeting both CD27 and PD-L1 (CD274), which may lead to enhanced immune activation (AACR Annual Meeting 2019, Abstract 2392, PMID: 32451681). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-527 | CDX527|CDX 527 | CD27 Antibody 3 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | CDX-527 is a tetravalent human antibody targeting both CD27 and PD-L1 (CD274), which may lead to enhanced immune activation (AACR Annual Meeting 2019, Abstract 2392, PMID: 32451681). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04440943 | Phase I | CDX-527 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | Completed | USA | 0 |